6.02
Schlusskurs vom Vortag:
$5.82
Offen:
$5.83
24-Stunden-Volumen:
160.16K
Relative Volume:
0.59
Marktkapitalisierung:
$148.24M
Einnahmen:
$34.26M
Nettoeinkommen (Verlust:
$-46.61M
KGV:
-1.162
EPS:
-5.1806
Netto-Cashflow:
$-62.01M
1W Leistung:
+10.63%
1M Leistung:
+30.07%
6M Leistung:
+5.75%
1J Leistung:
+30.07%
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DTIL
Precision Biosciences Inc
|
5.995 | 143.91M | 34.26M | -46.61M | -62.01M | -5.1806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Quarterly Recap: What is the long term forecast for Precision BioSciences Inc stockExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
FOMO Trade: How does Precision BioSciences Inc perform in inflationary periodsPortfolio Return Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Aug Action: Is Precision BioSciences Inc stock trending bullishInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
3.8M-share increase, director elections and charter change at Precision BioSciences (NASDAQ: DTIL) - Stock Titan
Will Precision BioSciences Inc be affected by tariffs2026 Biggest Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
VIX Spike: How does Precision BioSciences Inc compare to its peersQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Decliners Report: Is Rafael Holdings Inc Equity Warrant stock a good dividend stockProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Meme Stocks: What is the PEG ratio of Precision BioSciences Inc2026 Opening Moves & Risk Managed Investment Strategies - baoquankhu1.vn
Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday - MarketBeat
Q1 EPS Estimate for Precision BioSciences Raised by Analyst - MarketBeat
If You Invested $1,000 in Precision Biosciences (DTIL) - Stock Titan
Growth Value: How does Precision BioSciences Inc compare to its peers2026 Institutional Moves & AI Driven Stock Movement Reports - baoquankhu1.vn
Brokers Set Expectations for DTIL Q1 Earnings - MarketBeat
ETFs Investing in Precision BioSciences, Inc. Stocks - TradingView
Portfolio Recap: Is Precision BioSciences Inc likely to announce a buybackTrade Risk Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst CallSlideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design - Investing.com Canada
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design By Investing.com - Investing.com South Africa
Precision BioSciences Announces PBGENE-DMD Investor Update and Highlights ARCUS Gene Editing Platform – March 2026 - Minichart
Precision BioSciences Highlights PBGENE-DMD Program and Trial - TipRanks
PBGENE-DMD gene editing strategy at Precision BioSciences (NASDAQ: DTIL) - Stock Titan
Quarterly Risk: How volatile is Precision BioSciences Inc stockEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Precision BioSciences (DTIL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS
Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st
Precision BioSciences Inc buy Jefferies Financial Group Inc. - sharewise.com
Jefferies cuts Precision BioSciences stock price target on valuation By Investing.com - Investing.com Australia
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026 - Meyka
Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1%Here's Why - MarketBeat
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - PharmiWeb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and Statistics - IndexBox
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences (NASDAQ: DTIL) turns Q4 profit and extends cash runway to 2028 - Stock Titan
Precision BioSciences: Q4 Earnings Snapshot - Barchart.com
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):